Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 18 Jul 2022
Everest Medicines announces European Commission grants approval of Kinpeygo for adults with primary IgA nephropathy to our partner Calliditas Therapeutics
17 July 2022 - Kinpeygo (developed under the name Nefecon) is the first and only EMA approved treatment for IgAN. ...
Posted by Michael Wonder on 18 Jul 2022
Relief Therapeutics announces that its collaboration partner has resubmitted the ACER-001 (sodium phenylbutyrate) new drug application to the FDA for the treatment of urea cycle disorders
18 July 2022 - Relief Therapeutics today announced that its collaboration partner, Acer Therapeutics for ACER-001 (sodium phenylbutyrate) for oral ...
Posted by Michael Wonder on 18 Jul 2022
AbbVie submits marketing authorisation application to EMA for atogepant for the preventive treatment of migraine
18 July 2022 - The submission is based on two pivotal Phase 3 studies evaluating atogepant in adult patients with episodic ...
Posted by Michael Wonder on 17 Jul 2022
'Government excessively controls drug prices, not recognising novel drugs' value'
15 July 2022 - The Government is wielding excessive power to lower drug prices without recognising the values of innovative ...
Posted by Michael Wonder on 17 Jul 2022
Medicine affordability hardships bite for Australians as cost of living pressures build
18 July 2022 - Izzy Sheppard feels like they are constantly treading water to stay on top of medical expenses. ...
Posted by Michael Wonder on 17 Jul 2022
China CDE grants breakthrough therapy designation to Neurophth's NR082 in Leber's hereditary optic neuropathy
15 July 2022 - Neurophth Therapeutics today announced that the Center for Drug Evaluation of China National Medical Products Administration has ...
Posted by Michael Wonder on 17 Jul 2022
Prescription medication prices to rise
15 July 2022 - The price of nearly 900 prescription medications will rise by as much as $7 on October ...
Posted by Michael Wonder on 17 Jul 2022
COVID antivirals available by telehealth phone consultation
16 July 2022 - Medicare will cover a long consultation by a GP for the purpose of prescribing COVID-19 antivirals, with ...
Posted by Michael Wonder on 16 Jul 2022
UnitedHealthcare to offer $0 insulin, Epi-Pens, but only for some members
15 July 2022 - Next year, UnitedHealthcare will offer employer health plans that have no copays or out-of-pocket costs for five ...
Posted by Michael Wonder on 16 Jul 2022
Polpharma Biologics announces EMA acceptance of marketing authorisation application for proposed biosimilar natalizumab
14 July 2022 - Polpharma Biologics announced today that the EMA has accepted the first-ever marketing authorisation application for biosimilar natalizumab, ...
Posted by Michael Wonder on 16 Jul 2022
Monkeypox patients should not be left to suffer when an FDA approved drug could help
15 July 2022 - Andy couldn’t sleep more than a couple fitful hours a night because it felt like a ...
Posted by Michael Wonder on 15 Jul 2022
UK lags behind EU in authorising new medicines after Brexit
14 July 2022 - Experts attribute shortfall to small size of British market now it is regulated separately and complexity of ...
Posted by Michael Wonder on 15 Jul 2022
PBAC Public Summary Documents (first time rejections and deferrals) – March 2022 meeting
15 July 2022 - The Public Summary Documents (first time rejections and deferrals) from the March 2022 PBAC meeting are now ...
Posted by Michael Wonder on 15 Jul 2022
Health Canada authorises use of Moderna COVID-19 vaccine in children 6 months to 5 years of age
14 July 2022 - Today, Health Canada authorised the use of the Moderna Spikevax COVID-19 vaccine in children 6 months to ...
Posted by Michael Wonder on 15 Jul 2022
TGA approves Grifols' Xembify
15 July 2022 - Xembify is yet another presentation of human immunoglobulin. ...